trial · primary record
zongertinib
Neoplasm Metastasis
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 554 |
| Primary completion | 2029-08-29 |
| Primary endpoint | Phase Ia: Maximum Tolerated Dose (MTD) |
| Registry ID | NCT04886804 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:59.918Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04886804
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- ZONGERTINIB · approval
- Zongertinib · compound